ReviewInflammation2008
Platelet activating factor as a mediator and therapeutic approach in bronchial asthma.
Review in Inflammation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Ginkgolide B Alleviates Airway Inflammation in Hyperoxia Lung Injury.Immunity, inflammation and disease · 2026Article
- Association between platelet-to-neutrophil ratio and asthma-COPD overlap: a cross-sectional study in China.Frontiers in medicine · 2026Article
- Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation.Scandinavian journal of immunology · 2025Article
- Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- Platelet-activating factor and protease-activated receptor 2 cooperate to promote neutrophil recruitment and lung inflammation through nuclear factor-kappa B transactivation.Scientific reports · 2023Article
- Atopic asthma as a potentially significant but unrecognized risk factor for Kawasaki disease in children.The Journal of asthma : official journal of the Association for the Care of Asthma · 2022Article
- Emerging Roles of Platelets in Allergic Asthma.Frontiers in immunology · 2022Review
- MicroRNA miR-146a-5p inhibits the inflammatory response and injury of airway epithelial cells via targeting TNF receptor-associated factor 6.Bioengineered · 2021Article
- Review
- A new prenylated benzoquinone from Cyathocalyx pruniferus abrogates LPS-induced inflammatory responses associated with PGEInflammopharmacology · 2021Article
- PAF-R on activated T cells: Role in the IL-23/Th17 pathway and relevance to multiple sclerosis.Immunobiology · 2021Article
- Effect of Platelet-Activating Factor on Barrier Function of ARPE-19 Cells.Drug design, development and therapy · 2020Article
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.Molecules (Basel, Switzerland) · 2019Review
- Inflammation, not Cholesterol, Is a Cause of Chronic Disease.Nutrients · 2018Review
- Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells.Frontiers in pharmacology · 2018Article
- A new player in interstitial cystitis/bladder pain syndrome: platelet-activating factor - PAF and its connection to smoking.Physiological reports · 2017Article
- Role of interleukin-18 in the pathophysiology of allergic diseases.Cytokine & growth factor reviews · 2016Review
- Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets.Current allergy and asthma reports · 2016Review
- Sphingosine-1-phosphate and other lipid mediators generated by mast cells as critical players in allergy and mast cell function.European journal of pharmacology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet activating factor (PAF) is a potent phospholipid mediator involved in anaphylaxis and chronic inflammatory disorders, including bronchial asthma. PAF is able to act both, directly as a chemotactic factor and indirectly through the release of other inflammatory agents. Apart from its known potent ability to activate platelets, PAF influences other immune and inflammatory cells function involved in asthma, which may be of importance in the pathogenesis of the disease. In addition, PAF administration can mimic some of abnormalities observed in asthma, including bronchoconstriction, bronchial hyper responsiveness, and gas exchange impairment, which may be mediated by leukotrienes acting as secondary mediators of some PAF effects. Therefore, there has been an extensive interest in the role of PAF in human asthma and major efforts have been continued to discover drugs acting thorough inhibition of PAF effects in the disease. Surprisingly, PAF receptor antagonists have not clearly proven their clinical benefits. It may appear that the combined blockage of PAF effects and other mediators involved in asthma is a way to improve clinical efficacy and also an interesting approach to control inflammation in the disease. This review will focus on two main issues: the role of PAF and PAF antagonists in asthma.
Indexed as
Identifiers
18193345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.